首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

2046840

失智症藥物市場－全球產業規模、佔有率、趨勢、機會與預測：按適應症、藥物類別、地區和競爭格局分類，2021-2031年

Dementia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indications, By Drug Class, By Region & Competition, 2021-2031F

出版日期: 2026年05月25日 | 出版商:

TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球失智症治療市場預計將從 2025 年的 151.7 億美元大幅成長至 2031 年的 214.2 億美元，複合年成長率達到 5.92%。

該市場涵蓋多種旨在延緩認知衰退和解決神經退化性疾病根本原因的藥物，例如膽鹼酯酶抑制劑、NMDA受體拮抗劑和創新緩解疾病免疫療法。推動這一市場成長的主要動力是全球人口老化，這導致阿茲海默症和其他類型失智症的盛行率上升。不斷擴大的患者群體迫切需要治療性介入，從而刺激了藥物研發領域的大量投資。例如，據估計，到2025年，約有720萬65歲及以上的美國人將患有老年失智症失智症，凸顯了對有效治療方法的迫切需求。

市場概覽
預測期	2027-2031
市場規模：2025年	151.7億美元
市場規模：2031年	214.2億美元
複合年成長率：2026-2031年	5.92%
成長最快的細分市場	膽鹼酯酶抑制劑
最大的市場	北美洲

然而，儘管市場需求強勁，但臨床試驗的高失敗率卻阻礙了市場發展。神經退化性疾病複雜的生物特性導致後期研發階段成本高昂，失敗率居高不下，阻礙了投資，也使得監管核准更加困難。證明新型化合物的臨床療效這一持續挑戰，既是財務上的難題，也是營運上的障礙，阻礙了新治療方法的上市，並限制了全球整個行業的成長。

市場促進因素

失智症治療市場的主要驅動力是阿茲海默症及相關失智症在全球日益成長的盛行率。隨著全球預期壽命的延長，易患神經退化性疾病的老年人口也在增加，從而形成了一個龐大的患者群體，需要持續的藥物治療。這一人口趨勢給醫療保健系統帶來了巨大的經濟壓力，因此，開發能夠降低治療成本的有效療法已成為當務之急。例如，預計到2024年，美國用於治療阿茲海默症和其他失智症的費用將達到3,600億美元，凸顯了治療性介入的巨大經濟動力。同時，隨著創新疾病修正治療的出現，該產業正在經歷轉型，這些療法針對的是潛在的病理機制，而不僅僅是緩解症狀。近期抗澱粉樣蛋白藥物的監管核准標誌著一個重要的轉折點，證實了它們透過減少大腦中的斑塊來延緩疾病進展的科學有效性。例如，禮來公司的Kisunla™（donanemab-azbt）近期獲得FDA核准，在3期臨床試驗中證實，該藥可將認知和身體機能衰退的幅度降低高達35%。如此顯著的療效正迅速推動其商業化進程，生產規模也不斷擴大以滿足患者需求。以渤健公司的Lekenbi為例，該藥在2024年第三季全球銷售額約6,700萬美元，顯示市場對這類新型藥物有著強勁的初期需求。

市場挑戰

全球失智症治療市場面臨的主要障礙是臨床試驗的高脫落率。這個難題源自於神經退化性疾病複雜的病理生理機制，即使經過廣泛且昂貴的研究，也常導致後期藥物研發失敗。這些失敗給製藥公司帶來了沉重的經濟負擔，耗盡了資金，創造了規避風險的投資環境，從而減緩了新藥研發的步伐。因此，該行業面臨瓶頸，由於治療方法商業化案例寥寥無幾，收入成長和市場擴張直接受到阻礙。持續推動有效治療方法研發的困境進一步加劇了該產業正在努力解決的經濟挑戰。預計到2025年，美國國內用於照顧阿茲海默症和其他失智症患者的總成本將達到3,840億美元。這凸顯了巨大的未開發市場潛力，因為該產業尚未克服臨床障礙，也未能將核准的緩解疾病藥物提供給亟需治療的患者族群。

市場趨勢

針對Tau蛋白和神經發炎的研發開發平臺多元化正在顯著改變該領域的發展方向。這種方法超越了單純的BETA-澱粉樣蛋白積累，旨在解決神經退化性疾病複雜且多因素的發病機制。藥物研發人員正日益探索Tau聚集、突觸可塑性和神經發炎等機制，以克服單標靶治療的局限性，並改善更廣泛患者群體的臨床療效。這種策略轉變體現在針對這些新生物標的的臨床活動日益增加。截至2025年初，將有182項正在進行的臨床試驗，評估138種不同的候選藥物，這意味著非澱粉樣蛋白臨床實驗藥物的研發數量將顯著增加。同時，以血液為基礎的生物標記在患者分層和監測中的應用，為PET掃描和腰椎穿刺等侵入性且昂貴的診斷程序提供了便捷的篩檢工具，從而推動了市場成長。這些診斷技術的創新使得疾病能夠更早被發現，臨床試驗的患者篩選也更加精準，從而提高了藥物研發效率，並加速了緩解疾病療法的實施。新檢測方法的高診斷準確率支撐了這一趨勢的商業性潛力。一些血液檢測的準確率超過90%，遠高於傳統方法，證實了其在標準臨床實踐中的價值。

The global dementia drugs market is projected to expand significantly, from USD 15.17 billion in 2025 to USD 21.42 billion by 2031, achieving a compound annual growth rate (CAGR) of 5.92%. This market includes various pharmaceutical agents like cholinesterase inhibitors, NMDA receptor antagonists, and innovative disease-modifying immunotherapies, all aimed at reducing cognitive decline and targeting the root causes of neurodegenerative conditions. The main factor fueling this growth is the increasing global elderly population, which inherently leads to a higher prevalence of Alzheimer's disease and other dementias. This expanding patient demographic urgently requires therapeutic interventions, prompting considerable investment in drug discovery. For instance, in 2025, about 7.2 million Americans aged 65 and older are estimated to be living with Alzheimer's dementia, highlighting a critical and rising need for effective medical treatments.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 15.17 Billion
Market Size 2031	USD 21.42 Billion
CAGR 2026-2031	5.92%
Fastest Growing Segment	Cholinesterase Inhibitors
Largest Market	North America

However, despite this strong demand, the market is constrained by a high failure rate in clinical trials. The intricate biological nature of neurodegenerative diseases often leads to expensive late-stage development failures, deterring investment and complicating regulatory approvals. This ongoing challenge in proving the clinical effectiveness of new compounds poses a financial and operational obstacle, impeding the launch of new therapies and limiting the overall growth of the global industry.

Market Driver

The primary force driving the dementia drugs market is the increasing global prevalence of Alzheimer's disease and related dementias. With rising global life expectancy, the elderly population-more susceptible to neurodegenerative conditions-is growing, creating a vast patient base needing continuous pharmaceutical care. This demographic trend places substantial economic pressure on healthcare systems, making effective treatments to reduce care costs a top priority. For instance, in 2024, the cost of caring for individuals with Alzheimer's and other dementias in the United States was estimated at $360 billion, highlighting the significant financial motivation for therapeutic interventions. Concurrently, the introduction of innovative disease-modifying therapies is transforming the industry by targeting underlying pathologies rather than just symptoms. Recent regulatory approvals for anti-amyloid agents signify a pivotal shift, confirming the scientific viability of reducing brain plaque to slow disease progression. For example, Eli Lilly's Kisunla(TM) (donanemab-azbt), recently approved by the FDA, demonstrated a reduction in cognitive and functional decline by up to 35% in Phase 3 trials. Such efficacy is quickly leading to commercial adoption, with manufacturing expanding to meet patient needs, as evidenced by Biogen's Leqembi achieving approximately $67 million in global in-market sales in Q3 2024, indicating strong initial demand for this new class of drugs.

Market Challenge

A primary impediment to the global dementia drugs market is the high attrition rate in clinical trials. This difficulty arises from the complex pathophysiology of neurodegenerative diseases, which often causes drug candidates to fail in late-stage development following extensive and expensive research. These failures impose considerable financial strain on pharmaceutical companies, depleting capital and creating an investment environment averse to risk, thereby delaying new drug discovery initiatives. Consequently, the industry encounters a bottleneck where successful commercialization of innovative therapies is infrequent relative to the substantial investments made, directly hindering revenue growth and market expansion. This ongoing struggle to introduce effective treatments exacerbates the economic imperative that the industry is striving to address. The total national cost of caring for individuals with Alzheimer's and other dementias is projected to reach $384 billion in 2025, highlighting the vast market potential that remains untapped because the industry cannot surmount clinical obstacles and provide approved, disease-modifying agents to a waiting patient population.

Market Trends

The diversification of R&D pipelines to include tau protein and neuroinflammation targets is significantly reshaping the sector's direction. This approach addresses the intricate, multifactorial pathology of neurodegenerative diseases beyond just amyloid-beta accumulation. Pharmaceutical developers are increasingly exploring mechanisms such as tau aggregation, synaptic plasticity, and neuroinflammation to overcome the limitations of single-target therapies and enhance clinical results for a wider patient demographic. This strategic pivot is evident in the growing number of clinical activities focusing on these new biological targets; as of early 2025, there were 182 active clinical trials evaluating 138 unique drug candidates, marking a notable increase in non-amyloid investigative agents. Concurrently, the integration of blood-based biomarkers for patient stratification and monitoring is boosting market growth by offering accessible screening tools that replace invasive and expensive diagnostic procedures like PET scans and lumbar punctures. These diagnostic innovations facilitate earlier disease detection and more accurate patient selection for clinical trials, thereby streamlining drug development and enabling prompt administration of disease-modifying treatments. The commercial potential of this trend is underscored by the high diagnostic accuracy of new assays, with some blood-based tests demonstrating over 90% accuracy compared to traditional methods, confirming their value in standard clinical practice.

Key Market Players

AstraZeneca PLC
Aurobindo Pharma Limited
Eli Lilly & Co
Johnson & Johnson
Pfizer Inc
Teva Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Biogen Inc
GSK PLC
Merck & Co Inc

Report Scope

In this report, the Global Dementia Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dementia Drugs Market, By Indications

Alzheimer's Disease
Lewy Body Dementia
Parkinsons Disease Dementia
Vascular Dementia

Dementia Drugs Market, By Drug Class

Cholinesterase Inhibitors
Glutamate Inhibitors
MAO Inhibitors

Dementia Drugs Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dementia Drugs Market.

Available Customizations:

Global Dementia Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dementia Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, Vascular Dementia)
- 5.2.2. By Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Dementia Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Indications
- 6.2.2. By Drug Class
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Dementia Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Indications
    - 6.3.1.2.2. By Drug Class
- 6.3.2. Canada Dementia Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Indications
    - 6.3.2.2.2. By Drug Class
- 6.3.3. Mexico Dementia Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Indications
    - 6.3.3.2.2. By Drug Class

7. Europe Dementia Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Indications
- 7.2.2. By Drug Class
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Dementia Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Indications
    - 7.3.1.2.2. By Drug Class
- 7.3.2. France Dementia Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Indications
    - 7.3.2.2.2. By Drug Class
- 7.3.3. United Kingdom Dementia Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Indications
    - 7.3.3.2.2. By Drug Class
- 7.3.4. Italy Dementia Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Indications
    - 7.3.4.2.2. By Drug Class
- 7.3.5. Spain Dementia Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Indications
    - 7.3.5.2.2. By Drug Class

8. Asia Pacific Dementia Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Indications
- 8.2.2. By Drug Class
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Dementia Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Indications
    - 8.3.1.2.2. By Drug Class
- 8.3.2. India Dementia Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Indications
    - 8.3.2.2.2. By Drug Class
- 8.3.3. Japan Dementia Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Indications
    - 8.3.3.2.2. By Drug Class
- 8.3.4. South Korea Dementia Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Indications
    - 8.3.4.2.2. By Drug Class
- 8.3.5. Australia Dementia Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Indications
    - 8.3.5.2.2. By Drug Class

9. Middle East & Africa Dementia Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Indications
- 9.2.2. By Drug Class
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Dementia Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Indications
    - 9.3.1.2.2. By Drug Class
- 9.3.2. UAE Dementia Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Indications
    - 9.3.2.2.2. By Drug Class
- 9.3.3. South Africa Dementia Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Indications
    - 9.3.3.2.2. By Drug Class

10. South America Dementia Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Indications
- 10.2.2. By Drug Class
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Dementia Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Indications
    - 10.3.1.2.2. By Drug Class
- 10.3.2. Colombia Dementia Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Indications
    - 10.3.2.2.2. By Drug Class
- 10.3.3. Argentina Dementia Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Indications
    - 10.3.3.2.2. By Drug Class

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Dementia Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. AstraZeneca PLC
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Aurobindo Pharma Limited
15.3. Eli Lilly & Co
15.4. Johnson & Johnson
15.5. Pfizer Inc
15.6. Teva Pharmaceutical Industries Ltd
15.7. Zydus Lifesciences Ltd
15.8. Biogen Inc
15.9. GSK PLC
15.10. Merck & Co Inc